This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C ...

Kazia Therapeutics ( (KZIA) ) has provided an announcement.

XP-105 is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 30% phase transition ...

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update ...

The intricate link between endocrine disorders and cancer development has drawn significant interest, revealing how conditions like insulin resistance and ...

Dordaviprone hydrochloride is under clinical development by Chimerix and currently in Phase II for Relapsed Multiple Myeloma.

The developer’s vision for a 44-storey residential building at 2-4 Whitworth Street West has taken a step closer to reality  after the submission of a planning application to Manchester City Council.

Despite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

In recognising this UK Sport’s approach to funding reflects that journey and works on the basis of an athlete pathway with three clear and distinct levels that make up the World Class Pathway. The two ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...